Goodman Tony 4
4 · ADIAL PHARMACEUTICALS, INC. · Filed Apr 9, 2026
Research Summary
AI-generated summary of this filing
ADIL (Adial Pharmaceuticals) COO Tony Goodman Receives 26,510-Share Award
What Happened
- Tony Goodman, Chief Operating Officer of Adial Pharmaceuticals (ADIL), was granted 26,510 restricted shares on April 7, 2026. The shares were issued at an acquisition price of $0.00 (transaction code A — award/grant).
Key Details
- Transaction date: 2026-04-07; Form 4 filed 2026-04-09 (timely within the SEC’s 2-business-day window).
- Shares granted: 26,510 restricted common shares; acquisition price reported as $0.00.
- Shares owned after the transaction: not specified in this filing.
- Vesting/footnote: grant vests in full on the earlier of (i) the one‑year anniversary of the grant date (around 2027-04-07) or (ii) a Change of Control per the company’s 2017 Equity Incentive Plan, subject to Goodman’s continued service through the vesting date.
Context
- This is a compensation award (restricted stock) rather than an open‑market purchase or sale. Such grants are routine for employee compensation and are subject to vesting conditions; they do not by themselves indicate an insider buying or selling on market sentiment.
Insider Transaction Report
Form 4
Goodman Tony
DirectorChief Operating Officer
Transactions
- Award
Common Stock
[F1]2026-04-07+26,510→ 26,523 total
Footnotes (1)
- [F1]Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.
Signature
/s/ John Martin, Attorney-in-fact for Tony Goodman|2026-04-09